A comparative analysis of risk management strategies in European Union and United States pharmaceutical regulation

  title={A comparative analysis of risk management strategies in European Union and United States pharmaceutical regulation},
  author={Courtney Davis and John Abraham},
  journal={Health, Risk \& Society},
  pages={413 - 431}
Analyses of risk management within prescription pharmaceutical regulation are rare. We present the first comparison of pharmaceutical risk regulation between the EU's centralised supranational ‘state’ and another country, the US. Drawing on documentary and interview-based research on case-study drugs and risk management, we argue that ‘risk colonisation’, neo-liberal governmentality, and pressure from powerful industry interests have combined to produce permissive, rather than precautionary… 

From Regulatory Knowledge to Regulatory Decisions: The European Evaluation of Medicines

This article describes the main characteristics of European medicines regulation and the historical definition of what can count as “objective” evidence on the safety and efficacy of medicines and explains why experts manage to produce consensual opinions on medicines and why these opinions are considered genuine decisions in the sector.

Postmarket Safety Communication for Protection of Public Health: A Comparison of Regulatory Policy in Australia, Canada, the European Union, and the United States

The capacity of regulators in the United States, Europe, Canada, and Australia to warn about postmarket safety issues through safety advisories is examined by assessing their governance, legislative authority, risk communication capabilities, and transparency.

Drugs, risk and society: Government, governance or governmentality?

This themed issue of Health, Risk & Society on Drugs, Risk and Society brings together six articles reflecting the importance of drugs in the study of health risks. The articles fall into three

The will of Congress? Permissive regulation and the strategic use of labeling for the anti-influenza drug Relenza

It is argued that the Relenza case highlights contradictions between a scientific culture at FDA, conducive to rigorous product evaluations, and the agency’s attempts to accommodate higher-level political and industry demands conducive of permissive regulation.

Assessing risk by analogy: a case study of us medical device risk management policy

Examining market clearances of vaginal mesh surgical devices in the US finds that medical device regulation structurally favours innovation over safety, and ‘Light touch' risk assessment is not counterbalanced with postmarket mechanisms to safeguard against residual and developmental risks that are associated with medical devices, particularly permanent implants.

Drug Review Differences across the United States and the European Union

Harmonizing the drug regulatory environment of the United States (US) and European Union (EU) is becoming increasingly important to accelerate the development of new therapeutics.

Measuring the impact of the 2012 European pharmacovigilance legislation on additional risk minimization measures

ABSTRACT Aims: Additional risk minimization measures (aRMMs) may be needed to ensure that the benefits continue to outweigh the risks for medicines associated with serious risks. Prior research

The tools of globalization: ways of regulating and the structure of the international regime for pharmaceuticals

ABSTRACT This article investigates the relationship between regulatory globalization and neoliberal standard-setting arrangements building on industry capacities and responsibilities. Focusing on

Complaints, Complainants, and Rulings Regarding Drug Promotion in the United Kingdom and Sweden 2004–2012: A Quantitative and Qualitative Study of Pharmaceutical Industry Self-Regulation

Examining the evidence for promotion and self-regulation in the UK and Sweden found a discrepancy between the ethical standard codified in industry Codes of Conduct and the actual conduct of the industry.

Marx, Foucault, and state–corporate harm: a case study of regulatory failure in Australian non-prescription medicine regulation

Risk-based regulation has underpinned Australian prescription and non-prescription medicine regulation for over three decades. However, data consistently demonstrate high rates of non-compliance



Pharmaceutical risk communication: Sources of uncertainty and legal tools of uncertainty management

The purpose of this article is to differentiate between the different functions of pharmaceutical risk communication and make explicit their different legal natures and implications. Risk

Trading risks for markets: The international harmonisation of pharmaceuticals regulation

It is argued that this process of international harmonisation of pharmaceutical regulation is lowering regulatory standards regarding drug safety and is making the regulatory state more vulnerable to capture by industrial interests.

Risking public safety: Experts, the medical profession and ‘acceptable’ drug injury

The Althesin experience suggests that regulators, the medical profession and other stakeholders concerned about drug risks should focus their attention not only on improving the evidence-base of risk assessment, but also on more robust interpretation and informative communication of the evidence already available at any particular time.

Reforming regulation of the medical profession: The risks of risk-based approaches

Abstract Risk-based regulation is growing in popularity and in the UK has official backing as part of the government's modernization programme. State and non-state regulators alike are under pressure

Rethinking Innovation Accounting in Pharmaceutical Regulation

Regulatory policy-makers need much more sophisticated accounting systems for differentiating between drugs defined as significant therapeutic advances, and between drugs (‘therapeutic breakthroughs’ fast-tracked to treat serious or life-threatening conditions.

Precautionary Regulation in Europe and the United States: A Quantitative Comparison

The overall finding is of a mixed and diverse pattern of relative transatlantic precaution over the period, with some evidence of a modest shift toward greater relative precaution of European regulation since about 1990.

Emergent Patterns in the Regulation of Pharmaceuticals: Institutions and Interests in the United States, Canada, Britain and France

  • M. Wiktorowicz
  • Political Science
    Journal of health politics, policy and law
  • 2003
The regulatory approval processes and the government-industry relationships inherent within them are compared in the United States, Canada, Britain, and France by analyzing five features that distinguish the U.S. pluralist from the European corporatist approaches to policy development.

Pharmacopolitics: Drug Regulation in the United States and Germany

Arthur Daemmrich proposes that divergent "therapeutic cultures" - the interrelationships among governments, patients, the medical profession, and the pharmaceutical industry - underlie national differences and explain variations in pharmaceutical markets and medical care.

Drug Evaluation and the Permissive Principle

The concept of the `permissive principle' is developed as a way of understanding the departure of regulators' practices from standards of drug efficacy to which regulatory agencies themselves subscribe by taking a case study of antidepressant regulation in the UK and the USA.

Regulating Medicines in Europe: Competition, Expertise and Public Health

The authors argue that the drive to produce and approve more drugs more quickly for a single European market dominates other considerations, such as improvements in democratic accountability, the independence of regulators and scientific expertise from commercial interests, and drug safety testing and surveillance.